Journal of Visualized Experiments

Characterization and Functional Prediction of Bacteria in Ovarian Tissues --Manuscript Draft--

Article Type:	Invited Methods Article - Author Produced Video					
Manuscript Number:	JoVE61878R4					
Full Title:	Characterization and Functional Prediction of Bacteria in Ovarian Tissues					
Corresponding Author:	Qiling Li, Ph.D. Xi'an Jiaotong University Xi'an, CHINA					
Corresponding Author's Institution:	Xi'an Jiaotong University					
Corresponding Author E-Mail:	liqiling@mail.xjtu.edu.cn					
Order of Authors:	Lanbo Zhao					
	Weichu Zhao					
	Qi Wang					
	Dongxin Liang					
	Yu Liu					
	Guoxing Fu					
	Lu Han					
	Yiran Wang					
	Chao Sun					
	Qing Wang					
	Qing Song					
	Qiling Li, Ph.D.					
	Qinrui Lu					
Additional Information:						
Question	Response					
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$1200)					
Please confirm that you have read and agree to the terms and conditions of the author license agreement that applies below:	I agree to the Author License Agreement					
Please specify the section of the submitted manuscript.	Cancer Research					
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (\$1400)					
Please confirm that you have read and agree to the terms and conditions of the video release that applies below:	I agree to the Video Release					
Please provide any comments to the journal here.						

1 TITLE:

Characterization and Functional Prediction of Bacteria in Ovarian Tissues

2 3 4

AUTHORS AND AFFILIATIONS:

Lanbo Zhao^{1*}, Weichu Zhao^{2*}, Qi Wang^{1*}, Dongxin Liang¹, Yu Liu³, Guoxing Fu⁴, Lu Han¹, Yiran Wang¹, Chao Sun¹, Qing Wang¹, Qing Song¹, Qiling Li¹, Qinrui Lu¹

7

*These authors contributed to this work equally.

8 9

- 10 ¹Department of Obstetrics and Gynecology, First Affiliated Hospital of Xi'an Jiaotong
- 11 University, Xi'an, Shannxi, China
- 12 ²School of Social Sciences, University of Manchester, Manchester, UK
- 13 ³Department of Pathology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shannxi,
- 14 China
- ⁴Omega Bioservices Inc, Norcross, GA, USA

16

- 17 Email addresses of co-authors:
- 18 Lanbo Zhao (boboup2u@stu.xjtu.edu.cn)
- 19 Weichu Zhao (weichu.zhao@student.manchester.ac.uk)
- 20 Qi Wang (wangqiw@stu.xjtu.edu.cn)
- 21 Corresponding author:
- 22 Qiling Li (liqiling@mail.xjtu.edu.cn)
- 23 Qinrui Lu(junhuacao610@163.com)

24

25 **KEYWORDS**:

26 Ovarian cancer, Bacteria, 16S rRNA gene sequencing, Lipopolysaccharide, KEGG,

27 Immunohistochemistry

28 29

30

31

32

33

SUMMARY:

Immunohistochemistry staining and 16S ribosomal RNA gene (16S rRNA gene) sequencing were performed in order to discover and distinguish bacteria in cancerous and noncancerous ovarian tissues in situ. The compositional and functional differences of the bacteria were predicted by using BugBase and Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt).

343536

44

ABSTRACT:

The theory of a "sterile" female upper reproductive tract has been encountering increasing opposition due to advancements in bacterial detection. However, whether ovaries contain bacteria has not yet been confirmed yet. Herein, an experiment to detect bacteria in ovarian tissues was introduced. We chose ovarian cancer patients in the cancer group and noncancerous patients in the control group. 16S rRNA gene sequencing was used to differentiate bacteria in ovarian tissues from the cancer and control groups. Furthermore, we predicted the functional composition of the identified bacteria by using BugBase and PICRUSt.

This method can also be used in other viscera and tissues since many organs have been

proven to harbor bacteria in recent years. The presence of bacteria in viscera and tissues may help scientists evaluate cancerous and normal tissues and may be aid in the treatment of cancer.

INTRODUCTION:

Recently, an increasing number of articles have been published that prove the existence of bacteria in abdominal solid viscera, such as the kidney, spleen, liver, and ovary^{1,2}. Geller *et al.* found bacteria in pancreatic tumors, and these bacteria were resistant to gemcitabine, a chemotherapeutic drug². S. Manfredo Vieira *et al.* concluded that *Enterococcus gallinarum* was portable to the lymph nodes, liver and spleen, and it could drive autoimmunity³.

Since the cervix plays a role as a defender, bacteria in the upper female reproductive tract, which contains the uterus, fallopian tubes, and ovaries, have been minimally researched. However, some new theories have been established in recent years. Bacteria may have access to the uterine cavity during the menstrual cycle due to changes in mucins^{4,5}. Additionally, Zervomanolakis *et al.* confirmed that the uterus, together with the fallopian tubes, is a peristaltic pump controlled by the endocrine system of the ovaries, and this arrangement enables bacteria to enter the endometrium, fallopian tubes, and ovaries⁶.

The upper reproductive tract is no longer a mystery anymore thanks to the development of bacterial detection methods. Verstraelen *et al.* used a barcoded paired-end sequencing method to discover uterine bacteria by targeting at the V1-2 hypervariable region of the 16S RNA gene⁷. Fang *et al.* employed barcoded sequencing in patients with endometrial polyps and revealed the presence of diverse intrauterine bacteria⁸. Additionally, by using the 16S RNA gene, Miles *et al.* and Chen *et al.* found bacteria in the genital system of women who had undergone salpingo-oophorectomy and hysterectomy, respectively^{5,9}.

Bacteria in tumor tissues have gained increasing attention in recent years. Banerjee *et al.* discovered that the microbiome signature differed between ovarian cancer patients and controls¹⁰. Anoxynatronum sibiricum was associated with tumor stage, and Methanosarcina vacuolatamight may be used to diagnose ovarian cancer¹¹. In addition to ovarian cancer, other cancers, such as stomach, lung, prostate, breast, cervix, and endometrium, have been proven to be associated with bacteria¹²⁻¹⁸. Poore *et al.* proposed a new class of microbial-based oncology diagnostics, foreseeing early-stage cancer screening¹⁹. In this protocol, we investigated the differences between cancerous and normal ovarian tissues by comparing the composition and function of bacteria in these two tissues.

Immunohistochemistry staining and 16S rRNA gene sequencing were performed to confirm the presence of bacteria in the ovaries. The differences and predicted functions of the ovarian bacteria in cancerous and noncancerous ovarian tissues were studied. The results showed the existence of bacteria in ovarian tissues. *Anoxynatronum sibiricum* and *Methanosarcina vacuolata* were related to the stage and the diagnosis of ovarian cancer, respectively. Forty-six significantly different KEGG pathways that were present in both groups were compared.

PROTOCOL:

89 90

91 This study was approved by the Medical Institutional Ethics Committee of the First Affiliated 92 Hospital of Xi'an Jiaotong University (No. XJTUIAF2018LSK-139). Informed consent was 93 obtained from all enrolled patients.

94

1 Criteria for entering the cancer group and the control group

95 96 97

1.1.1 For the cancer group, enroll patients who are primarily diagnosed with ovarian cancer, and after laparotomy, they are proven to have serous ovarian cancer by pathological findings.

98 99 100

101

1.1.2 For the control group, enroll patients that are primarily diagnosed with uterine myoma or uterine adenomyosis, without presenting any ovarian condition, and who have undergone hysterectomy and salpingo-oophorectomy.

102103

NOTE: This standard is not definite. Patients with diseases not affecting the ovaries who undergo hysterectomy and salpingo-oophorectomy can also be enrolled.

106

- 107 1.2 Exclude patients with one or more of the following criteria:
- 108 Pregnant or breast-feeding women.
- 109 Taking antibiotics 2 months prior to the surgery.
- 110 Having fever or elevated inflammatory markers.
- 111 Having inflammation of any kind.
- Having undergone neoadjuvant chemotherapy.

113114

2 Gather samples

115

During the surgery, place the resected ovaries into a sterile tube and place the tube in liquid nitrogen for transport. Avoid touching anything else throughout the whole procedure.

118

Separate the ovaries into approximately 1-cm thick tissue samples with a pair of new
 sterile tweezers under a laminar flow cabinet. After separation, preserve samples at -80 °C.

121

NOTE: All the procedures for gathering samples are aseptic, including separating the ovaries.

123

124 3 Sequence the 16S rRNA gene

125

126 3.1 Extract DNA.

127

3.1.1 Add 1.2 mL of inhibit EX buffer into a 2 mL centrifuge tube. Then, add 180-220 mg of samples into the tube. Let the sample fully mix (70 °C water bath for 5 min and then vortex for

130 15 s).

131

132 3.1.2 Centrifuge the tube for 1 min at 600 x g.

- 134 3.1.3 Place 550 μL of the supernatant into a new 1.5 mL tube, and centrifuge for 1 min at
- 135 600 x g.

136

3.1.4 Transfer 400 μL of the supernatant with 30 μL of proteinase K into another 1.5 mL tube.

138

3.1.5 Add 400 μL of buffer AL and use a vortex mixer for 15 s.

140

141 3.1.6 Incubate at 70 °C for 10 min.

142

 $\,$ 3.1.7 $\,$ Add 400 μL of 96-100% alcohol. Use a vortex mixer for 15 s.

144

3.1.8 Transfer 600 μL of mixture into an absorption column and centrifuge for 1 min at 13700 g. Exchange the lower tube. Repeat this step 11 times.

147

- $\,$ 3.1.9 $\,$ Add 500 μL of buffer AW1, centrifuge for 1 min at 13,700 x g, and change the lower
- 149 tube.

150

- 3.1.10 Add 500 μ L of buffer AW2, centrifuge for 3 min at 13,700 x g, and change the lower
- 152 tube.

153

154 3.1.11 Centrifuge for 3 min at 13,700 x g.

155

3.1.12 Transfer the mixture into a new 1.5 mL tube, add 200 μL of buffer ATE, incubate at room temperature for 5 min and centrifuge for 1 min at 13,700 x g.

158

- 159 3.2 Quality testing. Use 1% Sepharose gel electrophoresis to test the quality. Add 400 ng of
- sample, 120 V, 30 mins. Ideal result: DNA concentration: \geq 10 ng/ μ L, DNA purity: A260/A280 =
- 161 1.8-2.0, gross DNA: ≥ 300 ng.

162

163 3.3 Prepare the libraries using a 16S metagenomic sequencing kit according to the 164 manufacturer's protocol.

165

3.3.1 Perform PCR. Briefly, each 25 μL PCR reaction contains 12.5 ng of sample DNA as input,
 167 12.5 μL of 2x KAPA HiFi HotStart ReadyMix and 5 μL of each primer at 1 μM.

168

- 169 3.3.2 Carry out PCR using the following protocol: an initial denaturation step performed at
- 95°C for 3 min followed by 25 cycles of denaturation (95°C, 30 s), annealing (55°C, 30 s) and
- extension (72°C, 30 s), and a final elongation of 5 min at 72°C.

172

173 3.3.3 Clean up the PCR product from the reaction mix with magnetic beads using the manufacturer's instructions.

175

176 3.3.4 Repeat steps 3.3.1 and 3.3.2.

177 178 3.3.5 Quality testing. Please refer to step 3.2. 179 180 3.3.6 Repeat step 3.3.3. 181 182 3.3.7 Quality testing. Use 1% Sepharose gel electrophoresis to test impurity, a 183 spectrophotometer to test purity, a fluorometer to test the concentration, and an RNA assay 184 kit to test integrity. Follow the manufacturer's protocol. Normalize and pool the libraries; then 185 sequence (2 x 300 bp paired-end read setting) using 600 cycle V3 standard flow cells, 186 producing approximately 100,000 paired-end 2 x 300 base reads. 187 188 NOTE: The full-length primer sequences: 16S Amplicon polymerase chain reaction (PCR) 189 Forward primer: 5' TCGTCGGCAGCGTCAGATGTGTATAAGA GACAG-[CCTACGGGNGGCWGCAG] and 16S Amplicon PCR Reverse primer: 5' GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG-190 191 [GACTACHVGGGTATCTAATCC]. 192 193 4 Analyze 16S rRNA gene sequencing data 194 195 Filter the raw reads of every sample based on sequencing quality with the software 4.1 196 package QIIME 2-201802²⁰. 197 198 4.1.1 Copy three files into the directory: emp-paired-end-sequences 01 199 one **forward.fastq.gz** file that contains the forward sequence reads, 200 one reverse.fastq.gz file that contains the reverse sequence reads, 201 one barcodes.fastq.gz file that contains the associated barcode reads 202 203 4.1.2 Execute 204 giime tools import \ 205 --type EMPPairedEndSequences \ 206 emp-paired-end-sequences 01 \--output-path --input-path emp-paired-end-207 sequences 02.gza 208 209 4.2 Remove the primer and adaptor sequences. 210 giime cutadapt trim-paired \ 211 --i-demultiplexed-sequences demultiplexed-seqs 02.qza \ 212 --p-front-f GCTACGGGGGG \ 213 --p-front-r GCTACGGGGGG \ 214 --p-error-rate 0 \ 215 --quality-cutoff 25 \ 216 --o-trimmed-sequences trimmed-seqs 03.gza \ 217 --verbose 218

Shorten sequence reads in which both paired-end qualities are lower than 25. See

219

220

4.3

above --quality-cutoff 25

```
221
222
       4.4
              Analyze the sequencing data.
223
224
       4.4.1 Gather sequences to form operational taxonomic units (OTUs) with a similarity cutoff
225
       at 97%.
226
       qiime vsearch dereplicate-sequences \
       --i-sequences trimmed-seqs_03.qza \
227
228
       --o-dereplicated-table table 04.gza \
229
       --o-dereplicated-sequences rep-seqs 04.qza
230
231
       qiime vsearch cluster-features-closed-reference \
232
       --i-table table 04.qza \
233
       --i-sequences rep-seqs 04.qza \
234
       --i-reference-sequences 97 otus.gza \
235
       --p-perc-identity 0.97 \
236
       --o-clustered-table table-cr-97.gza \
237
       --o-clustered-sequences rep-seqs-cr-97.qza \
238
       --o-unmatched-sequences unmatched-cr-97.gza
239
240
       4.4.2 For the OTUs, calculate the relative abundance in each sample. Abundance information
241
       is in table-cr-97.qza
242
243
              Employ a native Bayesian classifier, which aims at the RDP training set (version 9;
       4.5
244
       http://sourceforge.net/projects/rdp-classifier/), to sort all of the sequences. Mapped taxon
245
       information is in table-cr-97.gza
246
              Within the given OTU, assign a classification that reflects the major coherence of the
247
       4.6
248
       sequences to OTUs. Then, align the OTUs. See table-cr-97.gza and rep-seqs-cr-97.gza
249
250
       4.7
              Based on the sample group information, perform alpha diversity (including the Chao 1,
251
       ACE, Shannon, Simpson and Evenness indexes) and the UniFrac-based principal coordinates
252
       analysis (PCoA).
253
       qiime tools export \
254
       --input-path table-cr-97.gza \
255
       --output-path exported-feature-table
256
       exported-feature-table
257
258
       qiime diversity alpha \
259
       --i-table table-cr-97.qza \
260
       --p-metric observed otus \
261
       --o-alpha-diversity observed otus vector.gza
262
263
       giime diversity beta \
264
       --i-table table-cr-97.qza \
```

- 265 --p-metric braycurtis \
- 266 --o-distance-matrix unweighted_unifrac_distance_matrix.qza

5 Predict bacterial function

268269

- 5.1 To predict the related representation of the characteristics of the bacteria, use BugBase²¹. The input OTU table for BugBase is prepared using the following commands.
- 272 biom convert -i otu table.biom -o otu table.txt --to-tsv
- 273 biom convert -i otu table.txt -o otu table json.biom --table-type="OTU table" --to-json

274

NOTE: The prediction is based on six phenotype categories (Wardet al. unpublished)
(https://bugbase.cs.umn.edu/): Gram staining, oxygen tolerance, ability to form biofilms,

277 mobile element content, pathogenicity, and oxidative stress tolerance.

278

- 279 5.2 Predict the functional composition of a metagenome by PICRUSt with the usage of marker gene data and a database containing reference genomes²².
- 281 make_otu_table.py -i microbiome_97/uclust_ref_picked_otus/test_paired_otus.txt -t
- 282 /mnt/nas_bioinfo/ref/qiime2_ref/97_otu_taxonomy.txt -o otu_table.biom &
- 283 normalize_by_copy_number.py -i otu_table.biom -o normalized_otus.biom
- 284 predict_metagenomes.py -i normalized_otus.biom -o metagenome_predictions.biom
- 285 categorize_by_function.py -i metagenome_predictions.biom -c "KEGG_Pathways" -l 1 -o
- 286 picrust_L1.biom
- 287 categorize_by_function.py -f -i metagenome_predictions.biom -c KEGG_Pathways -l 1 -o
- 288 metagenome_predictions.L1.txt

289

290 5.3 Analyze the differences in functions among each group with the help of STAMP^{23,24}.
291 Please refer to the citations to operate the software.

292293

6 Data

294

295 6.1 Use statistical software to calculate the significance of the findings. The indication of statistical significance should be set as P < 0.05.

297

298 6.2. Assess differences in age and parity by Student's t-test. Assess differences in menopausal 299 status, history of hypertension and diabetes by the chi-square test. Assess differences in the 300 number of ovarian bacterial taxa by the Mann-Whitney U test.

301 302

303

REPRESENTATIVE RESULTS:

Patients

- 304 A total of 16 qualified patients were included in the study. The control group included 10
- women with a diagnosis of benign uterine tumor (among them, 3 patients were diagnosed with uterine myoma, and 7 patients were diagnosed with uterine adenomyosis). Meanwhile,
- 307 the cancer group contained 6 women with a diagnosis of serous ovarian cancer (among them,
- 2 patients were diagnosed with stage II, and 2 of them were diagnosed with stage III). The

following characteristics showed no differences between patients in the control group and the cancer group: age, menopausal status, parity, history of hypertension, and history of diabetes (**Table 1**).

[Table 1 here.]

The richness and variety of ovarian bacterial species in both groups

The alpha diversity of the microbes was analyzed as a method to detect the richness and variety of ovarian bacterial species. The number of species observed in the ovarian cancer tissues was smaller than that of the control group, with no significant difference. The richness (represented by the Chao 1 and ACE index) and the diversity (represented by the Shannon, Simpson, and Evenness index) of the bacterial species were both not significantly different between the cancer group and the control group (**Figure 2**).

[Figure 2 here.]

Description of ovarian bacteria

Deep sequencing of the V3-V4 16S rRNA gene region was performed on all samples to obtain a better understanding of the ovarian bacteria. The results showed that *Proteobacteria* was the most abundant phylum (67.10% in the control group and 67.20% in the cancer group), *Firmicutes* was the second most abundant phylum (23.77% in the control group and 23.82% in the cancer group), and the third most abundant phylum was *Bacteroidetes* (3.26% in the control group and 3.41% in the cancer group). When analyzing species of the control group, the main composition was consisted of *Halobacteroides halobios* (14.53%), followed by *Gemmata obscuriglobus* (11.07%) and *Methyloprofundus sedimenti* (10.69%). For the cancer group, *Gemmata obscuriglobus* was the richest in the cluster (13.89%), followed by *Halobacteroides halobius* (11.99%) and *Methyloprofundus sedimenti* (11.12%) (**Figure 3**).

[Figure 3 here.]

Different compositions of ovarian bacteria between the two groups

A comparison of different bacterial communities was carried out by PCoA using PERMANOVA. The results showed that the bacteria in the control group differed from those in the cancer group, P < 0.05 (Figure 4).

[Figure 4 here.]

Ovarian bacterial composition in cancer and control groups from different perspectives

An analysis of the ovarian bacterial composition was performed from different perspectives to further detect the differences in the identified ovarian bacteria. In **Table 2**, phylum, class, order, family, genus, and species levels were considered, and statistics are provided in the chart. In particular, there was an association between the relative abundance of *Anoxynatronum sibiricum* and the stage of the tumor, and *Methanosarcina vacuolata* was a specific sign when diagnosing ovarian cancer (**Table 2**).

Phenotypic conservation of ovarian bacteria in the two groups based on predicted functions

In the cancer group, the expression of genes related to potentially pathogenic and oxidative stress-tolerant phenotypes was increased compared with that of the control group (Wilcoxon signed-rank test, P = 0.02 and P = 0.002). No significant difference was found between the ovarian cancer and control groups in the following aspects: the phenotypes of aerobic, anaerobic, facultatively anaerobic, gram-positive, and gram-negative bacteria; mobile elements; and biofilm formation of the ovarian bacteria (**Figure 5**). Forty-six variant KEGG pathways between the bacteria in ovaries in the cancer and control groups were determined. The ovaries in the cancer group showed 26 increased pathways. Among them, the most highly related pathways were transporters. On the other hand, the bacteria in ovarian cancer tissue showed 20 reduced pathways. The most relevant functions were as follows: secretion system, unknown functions, and two-component system. The rest of the pathways are shown in **Figure 6**.

FIGURE AND TABLE LEGENDS:

Figure 1: LPS immunohistochemical expression in ovaries. (A) Control group (10 x). Scale bars, 200 μ m. (B) Control group (40 x). Scale bars, 50 μ m. (C) Cancer group (10x). Scale bars, 200 μ m. (D) Cancer group (40 x). Scale bars, 50 μ m. Arrows point to LPS staining in the ovarian tissue. We obtained reprint permission from previous publishers. This figure has been modified from Wang et al. 11.

Figure 2: 16S rRNA gene sequencing shows differences between the cancer and control groups in bacterial richness and diversity. (A) Observed species index (P = 0.06, Mann-Whitney U test); (B) Chao 1 index (P = 0.06, Mann-Whitney U test); (C) ACE index (P = 0.06, Mann-Whitney U test); (D) Shannon index (P = 0.32, Mann-Whitney U test; E. Evenness index (P = 0.48, Mann-Whitney U test); (F) Simpson index (P = 0.46, Mann-Whitney U test). We obtained reprint permission from previous publishers. This figure has been modified from Wang et al.¹¹.

Figure 3: Relative abundance of phyla (> 1%) and of the top 12 species in ovarian samples. (A) The relative abundance of the phyla (> 1%) in the ovaries of the patients in the control group. (B) The relative abundance of the phyla (> 1%) in the ovaries of patients with ovarian cancer. (C) The relative abundances of the 12 most abundant bacterial species in the ovaries of the control patients. (D) The relative abundances of the 12 most abundant bacterial species in the ovaries of ovarian cancer patients. We obtained reprint permission from previous publishers. This figure has been modified from Wang et al.¹¹.

Figure 4: PCoA detects clusters of communities and the relative abundances of Anoxynatronum sibiricum and Methanosarcina vacuolata. (A) Communities were clustered using PCoA. PC1 and PC2 are plotted on the x and y axes. The red block indicates a sample in the ovarian cancer group. The blue circle indicates a sample in the control group. The samples from the ovarian cancer group were separated from other samples in the control group. (B) Communities clustered using PCoA. PC1 and PC2 are plotted on the x and y axes. The red block

indicates a sample in the ovarian cancer group. The blue solid circle indicates a sample from a patient with uterine myoma, and the blue hollow circle is equal to a sample of a patient with uterine adenomyosis. (C) The relative abundance of *Anoxynatronum sibiricum* (control group: n = 10, cancer group: n = 6, P = 0.034, Mann-Whitney U test). (D) The relative abundance of *Methanosarcina vacuolata* (control group: n = 10, cancer group: n = 6, P = 0.001, Mann-Whitney U test). We obtained reprint permission from previous publishers. This figure has been modified from Wang et al.¹¹.

Figure 5: Predicted metagenomes analyzed by BugBase. The expression of some genes in the cancer group was increased compared with that in the control group. These genes were related to potentially pathogenic (Wilcoxon signed-rank test, P = 0.02) and oxidative stresstolerant phenotypes of the ovaries. (Wilcoxon signed-rank test, P = 0.002). We obtained reprint permission from previous publishers. This figure has been modified from Wang et al.¹¹.

Figure 6: PICRUSt analysis of different KEGG pathways between the cancer and control groups. We obtained reprint permission from previous publishers. This figure has been modified from Wang et al.¹¹.

Table 1: Patient statistics

Table 2: Richness (represented by the Chao 1 and ACE index) and the diversity (represented by the Shannon, Simpson, and Evenness index) of the bacterial species

DISCUSSION:

Ovarian cancer has a notable influence on women's fertility²⁵. Most ovarian cancer patients are diagnosed at late stages, and the 5-year survival rate is less than 30%¹⁸. Confirmation of bacteria in the abdominal solid viscera, including the liver, pancreas and spleen, has been published. The existence of bacteria in the upper female reproductive tract occurs because the cervix is not enclosed²⁻⁵. However, whether ovaries, which are abdominal solid viscera, are sterile or not has not yet been determined. Additionally, whether bacteria in the ovaries are related to ovarian cancer is also an important question.

The significant differences in the bacteria that we found were compared between different groups. All of the procedures mentioned above were strictly germfree, including instruments, reagents, equipment, and the operation of the whole protocol. More importantly, we used ovaries from patients with benign uterine disease as the control group to counteract possible contamination. However, in this protocol, contamination cannot be avoided. Thus, since the cancer group and control group were analyzed in the same experimental environment, merely by comparing the differences between these two groups, we could obtain primary evidence about the microbiological origin of ovarian cancer.

The findings of bacteria in ovarian tissue might start a new field investigating the bacteria influencing ovarian cancer. Additionally, the unique presence and composition of bacteria in cancerous ovarian tissues might direct the carcinogenesis of ovarian cancer, and the

therapeutic and prognostic targets of bacteria. Among the 46 KEGG pathways, functions related to the biosynthesis of vancomycin group antibiotics drew particular attention. This may provide further treatment options for ovarian cancer.

However, the protocol had some limitations. First, the samples could not be collected from healthy people for ethical reasons. The control group was ovaries of patients with benign uterine disease (including uterine myoma and adenomyosis). Second, the number of samples should be larger. The limited sample size of the study might hamper the accuracy of the results. Third, although the cancer group and the control group were under the same conditions, there were no negative or positive controls. In addition, contamination could not be avoided. To date, the study of the ovarian bacteria in patients with ovarian cancer is still in an early stage. A larger-scale study with more samples is needed.

ACKNOWLEDGMENTS:

This work was supported by the Clinical Research Award of the First Affiliated Hospital of Xi'an Jiaotong University, China (XJTU1AF-2018-017, XJTU1AF-CRF-2019-002), the Major Basic Research Project of Natural Science of Shaanxi Provincial Science and Technology Department (2018JM7073, 2017ZDJC-11), the Key Research and Development Project of Shaanxi Provincial Science and Technology Department (2017ZDXM-SF-068, 2019QYPY-138), the Shaanxi Provincial Collaborative Technology Innovation Project (2017XT-026, 2018XT-002), and the Medical Research Project of Xi'an Social Development Guidance Plan (2017117SF/YX011-3). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

We thank the colleagues in the Department of Gynecology of First Affiliated Hospital of Xi'an Jiaotong University for their contributions to collecting samples.

DISCLOSURES:


The authors have nothing to disclose.


REFERENCES:


- 472 1 Manfredo Vieira, S. *et al.* Translocation of a gut pathobiont drives autoimmunity in mice and humans. *Science.* **359** (6380), 1156-1161 (2018).
- 474 2 Geller, L. T. *et al.* Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. *Science.* **357** (6356), 1156-1160 (2017).
- 476 3 Manfredo, V. S. *et al.* Translocation of a gut pathobiont drives autoimmunity in mice and humans. *Science.* **359** (6380), 1156-1161 (2018).
- 478 4 Brunelli, R. *et al.* Globular structure of human ovulatory cervical mucus. *FASEB J.* **21** (14), 3872-3876 (2007).
- 5 Chen, C. *et al.* The microbiota continuum along the female reproductive tract and its relation to uterine-related diseases. *Nature Communications.* **8** (1), 875 (2017).
- 482 6 Zervomanolakis, I. *et al.* Physiology of upward transport in the human female genital 483 tract. *Annals of the New York Academy of Sciences.* **1101**, 1-20 (2007).
- 484 7 Verstraelen, H. et al. Characterisation of the human uterine microbiome in non-


- pregnant women through deep sequencing of the V1-2 region of the 16S rRNA gene.


 486 *PeerJ.* **4**, e1602 (2016).
- Fang, R. L. *et al.* Barcoded sequencing reveals diverse intrauterine microbiomes in patients suffering with endometrial polyps. *American Journal of Translational Research.* **8** (3), 1581-1592 (2016).
- 490 9 Miles, S. M., Hardy, B. L. & Merrell, D. S. Investigation of the microbiota of the 491 reproductive tract in women undergoing a total hysterectomy and bilateral salpingo-492 oopherectomy. *Fertil Steril.* **107** (3), 813-820 e811 (2017).
- 493 10 Banerjee, S. *et al.* The ovarian cancer oncobiome. *Oncotarget.* **8** (22), 36225-36245 494 (2017).
- Wang, Q. *et al.* The differential distribution of bacteria between cancerous and noncancerous ovarian tissues in situ. *Journal of Ovarian Research.* **13** (1), 8 (2020).
- Wang, L. *et al.* Bacterial overgrowth and diversification of microbiota in gastric cancer. *European Journal of Gastroenterology & Hepatology.* **28** (3), 261-266 (2016).
- Hosgood, H. D., 3rd *et al.* The potential role of lung microbiota in lung cancer attributed to household coal burning exposures. *Environmental and Molecular Mutagenesis.* **55** (8), 643-651 (2014).
- 502 14 Kwon, M., Seo, S. S., Kim, M. K., Lee, D. O. & Lim, M. C. Compositional and Functional Differences between Microbiota and Cervical Carcinogenesis as Identified by Shotgun Metagenomic Sequencing. *Cancers.* **11** (3), 309 (2019).
- 505 15 Urbaniak, C. *et al.* The Microbiota of Breast Tissue and Its Association with Breast 506 Cancer. *Applied and Environmental Microbiology.* **82** (16), 5039-5048 (2016).
- Feng, Y. *et al.* Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer. *BMC Genomics.* **20** (1), 146 (2019).
- Walsh, D. M. *et al.* Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome). *Scientific Reports.* **9** (1), 19213 (2019).
- Walther-Antonio, M. R. *et al.* Potential contribution of the uterine microbiome in the development of endometrial cancer. *Genome Medicine*. **8** (1), 122 (2016).
- Poore, G. D. *et al.* Microbiome analyses of blood and tissues suggest cancer diagnostic approach. *Nature.* **579** (7800), 567-574 (2020).
- Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics.* **30** (15), 2114-2120 (2014).
- 517 21 Ward, T. *et al.* BugBase predicts organism-level microbiome phenotypes. *bioRxiv.* 10.1101/133462 133462 (2017).
- Langille, M. G. *et al.* Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. *Nature Biotechnology.* **31** (9), 814-821 (2013).
- Langille, M. G. I. *et al.* Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. *Nature Biotechnology.* **31** (9), 814 (2013).
- Parks, D. H., Tyson, G. W., Hugenholtz, P. & Beiko, R. G. STAMP: statistical analysis of taxonomic and functional profiles. *Bioinformatics*. **30** (21), 3123 (2014).
- Leranth, C. & Hamori, J. "Dark" Purkinje cells of the cerebellar cortex. *Acta Biologica Hungarica*. **21** (4), 405-419 (1970).














Cancer group

Control group

	Control	Cancer	
	group (n=10)	group	P value
Age	51. 6 (45- 57)		0. 29
Menopaus al status			0. 12
Pre/Peri	8	2	
Post	2	4	
Parity	5. 1 (1- 13)	3.1 (2-5)	0. 17
History of hyperten sion Yes No	1 9	2 4	0. 52
History of diabetes			0.7
Yes No Stage	1 9	1 5	
(%) II III Histotyp e (%)		2 (33.3) 4 (66.7)	
Uterine myoma	3 (30)	-	
Uterine adenomyo sis	7 (70)	_	
Ovarian serous carcinom a	_	6 (100)	

		Control cohort (n=10, %)	Ovarian tumor cohort (n = 6, %)	P value
Phylum	Planctomy cetes	0.5144 ± 0.1420		0.023
	Crenarcha eota	0. 2840 ± 0. 0787	0. 1592 ± 0. 0775	0.023
	Aquificae	0.0352 ± 0.0137	0.0697 ± 0.0291	0.017
Class	Spartobac teria	0.3149 ± 0.0923	0. 4795 ± 0. 1205	0.026
	Sphingoba cteriia	0.1280 ± 0.0695	0.0423 ± 0.0706	0.039
Order	Planctomy cetales	7. 2700 ± 1. 3880	9. 1183 ± 0. 8594	0.039
	Pseudomon adales	0. 1332 ± 0. 0746	0. 4283 ± 0. 4019	0.023
	Enterobac teriales		2. 0105 ± 2. 5829	0.03
	Methanoba cteriales	0. 1626 ± 0. 0496	0. 2602 ± 0. 0859	0.03
	Halobacte riales	0.0648 ± 0.0117	0. 0439 ± 0. 0287	0.039
		0.0776 ± 0.0158		0.009
Family	Flavobact eriaceae	24. 7500 ± 0. 6712	21.7167 ± 3.0732	0.014
	Methanoba cteriacea e	$0.1720 \pm$	0. 2667 ± 0. 0867	0.039
	Moraxella ceae	0.1328 ± 0.0658	0. 4347 ± 0. 4054	0.03
	Petrotoga ceae	0.0452 ± 0.0178	0.0638 ± 0.0112	0.039
	Thermacea e	0.0078 ± 0.0089	0.0188 ± 0.0086	0.017

	Archaeogl obaceae	0. 0611 0. 0221	±	0. 0381 0. 0123	±	0.045
	Leptotric hiaceae	0. 1018 0. 0524	±	0. 0442 0. 0284	±	0.03
	Microbact eriaceae	0. 1493 0. 0618	±	0. 2740 0. 1320	\pm	0.039
	Staphyloc occaceae	0.0545		0.0536		
	Thermogem matispora ceae	0. 1923		0.0962		
	Methanoco rpusculac eae	0.0139		0.0003		
	Geodermat ophilacea e	0.0555		0.0143		
Genus	Paenibaci 11us	0. 7990 0. 4563	±	0. 3207 0. 2151	±	0.039
	Haloferul a	0.0623		0. 0263		
	Subdivisi on	0. 0801 0. 0314	\pm	0. 0465 0. 0188	±	0.039
	Zavarzine 11a	0. 0741 0. 0238	\pm	0. 1234 0. 0305	±	0.009
	Photorhab dus	0. 0013 0. 0029	\pm	0.0068 0.0050	±	0.023
	Volucriba cter	0. 0081 0. 0062	±	0. 0021 0. 0046	±	0.042
	Blastococ cus	0. 0552 0. 0335	±	0. 0144 0. 0145	±	0.03
	Mesotoga	0. 2509 0. 0703	±	0. 3675 0. 1057	±	0.039
	Defluviit oga	0. 0550 0. 0252	±	0. 0216 0. 0114	±	0.03
	Dorea	0. 0063 0. 0065	±	0.0000 0.0000	±	0.025
Species	Rhodopire 11ularubr a		<u>+</u>	0. 7563 0. 2398	±	0.013

Haloferul asargassi cola	0. 1534 0. 0629	±	0. 0999 0. 0227	\pm	0.03
Thermogem matispora foliorum	0. 7813 0. 2152	\pm	1. 4957 0. 6735	\pm	0.023
Mycoplasm aequigeni talium	0. 5463 0. 0684	\pm	0. 6820 0. 1108	<u>±</u>	0.039
Bifidobac teriumsub tile	0. 0924 0. 0269	\pm	0. 2584 0. 1958	\pm	0.026
Natroniel laacetige na	0. 0075 0. 0078	±	0.0000 0.0000	\pm	0.012
Flammeovi rgakamoga wensis	0. 6966 0. 3523	±	0. 2488 0. 1349	\pm	0.026
Eubacteri umyurii	0. 0231 0. 0111	±	0. 0091 0. 0074	±	0.03
Enterococ cusdiestr ammenae	0. 2549 0. 0859	土	0. 1458 0. 0809	<u>+</u>	0.03
Pelagicoc cusalbus	0. 0127 0. 0057	\pm	0.0047 0.0024	\pm	0.017
Fodinibac terluteus	0. 1588 0. 0461	\pm	0. 0935 0. 0498	<u>±</u>	0.039
Prostheco bacteralg ae	0. 0210 0. 0121	\pm	0.0080 0.0050	\pm	0.03
Emticicia oligotrop hica	0. 0743 0. 0297	\pm	0. 0308 0. 0251	\pm	0.013
Leuconost occitreum		±	0. 0108 0. 0125	\pm	0.039
Methanimi crococcus blatticol		\pm	0. 1572 0. 0383	\pm	0.039
a Methanosa rcinavacu olata	0. 0156 0. 0061	±	0. 0007 0. 0015	\pm	0.001
Lactobaci llussucic ola	0. 0160 0. 0063	\pm	0.0081 0.0053	<u>+</u>	0.03
Caldicopr obacteros himai	0. 0014 0. 0041	\pm	0. 0044 0. 0042	<u>±</u>	0.048

```
Caldicell
ulosirupt 0.3268 \pm 0.1082 \pm 0.039
orsacchar 0.1880 0.1296
olyticus
 \begin{array}{c} \text{Methylomi} \\ \text{crobiumal} \\ 0.0021 \end{array} \begin{array}{c} 0.0069 \\ 0.0051 \end{array} \begin{array}{c} \pm \\ 0.013 \end{array} 
Novispiri 0.0031 \pm 0.0000 \pm 0.048 11um 0.0036 \pm 0.0000
0.0036 0.0000 itersonii
Paenibaci 0.6905 \pm 0.2356 \pm 0.039
11usodori 0.4128 0.1583
agenitali 0.0038 0.0048
um
Sulfurosp
irillumha 0.0630 \pm 0.0948 \pm 0.039
lorespira 0.0163 0.0306
ns
Streptoco 0.0514 \pm 0.0190 \pm 0.03
ccuscasto 0.0415 0.0329
reus
Spongiivi 0.2355 \pm 0.0921 \pm 0.039
rgacitrea 0.1391 0.0784
Staphyloc occuscapi 0.0245 \pm 0.0752 \pm 0.021 0.0504 \pm 0.0506
Xanthomon 0.0094 \pm 0.0000 \pm 0.025
asbromi 0.0117 0.0000
Vulcanisa
eta 0.0457 \pm 0.0720 \pm 0.039
thermophi 0.0106 0.0247
la
0.0081 \pm 0.0021 \pm 0.042
          0.0062 0.0046
amazonae
Thalassot 0.0316 \pm 0.0027 \pm 0.004
          0.0202 0.0045
fusca
0.0074 0.0000
veroralis
```

```
Pseudobut
yrivibrio 0.0072 \pm 0.0021 \pm 0.03
xylanivor 0.0063 0.0046
ans
Peptoniph
ilus 0.0000 \pm 0.0031 \pm 0.017
methionin 0.0000 0.0033
ivorax
Sphingoba 0.2488 \pm 0.0861 \pm 0.03
cterium 0.1235 0.0529
arenae
Campyloba 0.0050 \pm 0.0000 \pm 0.048
         0.0064 0.0000
rectus
Blautia 0.0166 \pm 0.0056 \pm 0.033
glucerase 0.0091 0.0067
Calditerr 0.0745 \pm 0.1084 \pm 0.023
        0. 0158 0. 0306
vamamurae
Clostridi
um 0.0036 \pm 0.0127 \pm 0.03
thermosuc 0.0051 0.0089
cinogenes
Alkalibac
illus 0.0058 \pm 0.0000 \pm 0.025
haloalkal 0.0066 0.0000
iphilus
Acholepla 0.0038 \pm 0.0000 \pm 0.025
sma oculi 0.0041 0.0000
Aureimona
s 0.0013 \pm 0.0068 \pm 0.023
phyllosph 0.0029 0.0050
aerae
Azonexus hydrophil 0.0773 \pm 0.0285 \pm 0.007 0.0316 \pm 0.0190
Anaerosti
pes 0.0005 \pm 0.0045 \pm 0.025
rhamnosiv 0.0015 0.0043
orans
sibiricum
Legionel1
a 0.0029 \pm 0.0000 \pm 0.048
taurinens 0.0031 0.0000
is
```

```
Mesonia 0.0119 \pm 0.0031 \pm 0.019
phycicola 0.0087 0.0033
Luteoliba
cter 0.2389 \pm 0.4292 \pm 0.03
cuticulih 0.1090 0.1517
irudinis
Megasphae 0.0052 \pm 0.0000 \pm 0.025
ra indica 0.0055 0.0000
Dorea
formicige 0.0063 \pm 0.0000 \pm 0.025 0.0065 + 0.0000
nerans
Fuchsiell
        0.0082 \pm 0.0014 \pm 0.043
a
alkaliace 0.0075 0.0031
tigena
Geobacil1
thermoden triffican 0.0063 \pm 0.0006 \pm 0.024
```

Table of Materials

Click here to access/download **Table of Materials**JoVE_Table_of_Materials.xlsx

Editorial comments:

Changes to be made by the Author(s) regarding the written manuscript: None.

Changes to be made by the Author(s) regarding the video:

Composition

08:41 - A random black border appears during this figure. Please make the background all white so we don't see the edge of the figure.

Please upload a revised high-resolution video here:

https://www.dropbox.com/request/DYGKknA7Z8tk598ICK1w?oref=e

or

https://www.jove.com/account/file-uploader?src=18872838

or

any way you can and I can download the revised video.

Response: Thank you for your suggestion. We have submitted our latest video.


June 26, 2021

Dear Zhao,

Thank you for your letter. I have known that your under-reviewed protocol "Characterization of Bacteria in Ovarian Tissues and Functional Prediction of These Bacteria" has some figures reprinted from the article "The differential distribution of bacteria between cancerous and noncancerous ovarian tissues in situ". We permitted the reprint.

Sincerely,





Qiling Li



Certificate of Elsevier Language Editing Services

The following article was edited by Elsevier Language Editing Services:

"Characterization of Bacteria in Ovarian Tissues and Functional Prediction of These Bacteria"

Authored by: Qiling Li

Date: 19-Jul-2021

Serial number: LE-216501-9A68E386AADE

